TB medicine pricing worry

ISLAMABAD – Swiss pharmaceuticals firm Novartis AG said it had stopped making tuberculosis drugs in Pakistan in a dispute over pricing, prompting fears of a health crisis because of a shortage of drugs in a country with the world’s fifth-highest TB rates. As in many developing countries, the Drug Regulatory Authority of Pakistan (DRAP) sets […]

Continue reading this article with a Fiji Times online membership.

More Stories